This study evaluates the effectiveness of the topical use of an aerosol foam combination of calcipotriol 50 mu g/g plus betamethasone dipropionate 0.5 mg/g (Cal/BD foam, Enstilar (R)) in adults with moderate plaque psoriasis. A total of 120 male and female adult psoriasis patients (53.3% male) from two Italian dermatological units were enrolled in an 8-week prospective study performed between November 2018 and January 2019. Psoriasis Area and Severity Index (PASI) was evaluated at baseline (T0) and 4 weeks (T4) of daily application, and a further evaluation was carried out 4 weeks after suspension (T8). Furthermore, the Dermatology Life Quality Index (DLQI) was evaluated at baseline and after 4 weeks of treatment (T4). At baseline, patients presented a mean PASI of 7 (7.0 +/- 2.1). After 4 weeks (T4) of once-daily application, an important improvement in PASI was observed (1.1 +/- 0.3). At Week 4, DLQI was reduced by 5.5 points from baseline (mean: 12 +/- 3.1 at T0 vs 6.5 +/- 1.8 at T4). Four weeks after suspension (T8), mean PASI was 2.6 +/- 1.9, which was stable compared to the previous evaluation; only 8.3% of the treated patients showed worsening of plaque psoriasis. This study suggested that the Cal/BD aerosol foam is an effective topical therapy to treat plaque psoriasis.

Dattola, A., Silvestri, M., Bennardo, L., Passante, M., Rizzuto, F., Dastoli, S., et al. (2020). A novel vehicle for the treatment of psoriasis. DERMATOLOGIC THERAPY, 33(1), e13185 [10.1111/dth.13185].

A novel vehicle for the treatment of psoriasis

Bianchi L.;
2020-01-01

Abstract

This study evaluates the effectiveness of the topical use of an aerosol foam combination of calcipotriol 50 mu g/g plus betamethasone dipropionate 0.5 mg/g (Cal/BD foam, Enstilar (R)) in adults with moderate plaque psoriasis. A total of 120 male and female adult psoriasis patients (53.3% male) from two Italian dermatological units were enrolled in an 8-week prospective study performed between November 2018 and January 2019. Psoriasis Area and Severity Index (PASI) was evaluated at baseline (T0) and 4 weeks (T4) of daily application, and a further evaluation was carried out 4 weeks after suspension (T8). Furthermore, the Dermatology Life Quality Index (DLQI) was evaluated at baseline and after 4 weeks of treatment (T4). At baseline, patients presented a mean PASI of 7 (7.0 +/- 2.1). After 4 weeks (T4) of once-daily application, an important improvement in PASI was observed (1.1 +/- 0.3). At Week 4, DLQI was reduced by 5.5 points from baseline (mean: 12 +/- 3.1 at T0 vs 6.5 +/- 1.8 at T4). Four weeks after suspension (T8), mean PASI was 2.6 +/- 1.9, which was stable compared to the previous evaluation; only 8.3% of the treated patients showed worsening of plaque psoriasis. This study suggested that the Cal/BD aerosol foam is an effective topical therapy to treat plaque psoriasis.
2020
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35 - MALATTIE CUTANEE E VENEREE
English
betamethasone dipropionate; calcipotriol drug combination; foam; psoriasis; treatment effectiveness
Dattola, A., Silvestri, M., Bennardo, L., Passante, M., Rizzuto, F., Dastoli, S., et al. (2020). A novel vehicle for the treatment of psoriasis. DERMATOLOGIC THERAPY, 33(1), e13185 [10.1111/dth.13185].
Dattola, A; Silvestri, M; Bennardo, L; Passante, M; Rizzuto, F; Dastoli, S; Patruno, C; Bianchi, L; Nistico, Sp
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Dattola_et_al-2020-Dermatologic_Therapy.pdf

solo utenti autorizzati

Licenza: Copyright dell'editore
Dimensione 862.86 kB
Formato Adobe PDF
862.86 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/235133
Citazioni
  • ???jsp.display-item.citation.pmc??? 21
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 31
social impact